test

Flynn Management LLC, its general partner

@Deerfield Management Company, L.p. (series C)

Latest period2024 - Q3ReportedManaged Assets$6.693BTotal holdings443
Assets growth rate11.36%Assets growth rate (2-Q avg)7.96%Continuous growth in asset value4 quarters

Portfolio positions

This chart displays the top 10 holdings in Deerfield Management Company, L.p. (series C)'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 443 positions.

Assets under management

The assets under management (AUM) of Deerfield Management Company, L.p. (series C) over the past 10 years (40 quarters) show continuous growth in total asset value over the last 4 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 6.693B in assets, with a quarterly growth rate of 11.36% and a 2-quarter average growth rate of 7.96%. The portfolio is managed by Flynn Management LLC, its general partner, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
VTRSViatris Inc
Recent Activity
Increased 12.15%
4.17%
$278.559M
23.993M shares@ $11.61 avg price
CNCCentene Corp Del
Recent Activity
Increased 0.08%
2.99%
$199.657M
2.652M shares@ $75.29 avg price
MRUSMerus N V
Recent Activity
Increased 23.98%
2.55%
$170.291M
3.409M shares@ $49.96 avg price
OSCROscar Health Inc
Recent Activity
Increased 12.82%
2.49%
$166.534M
7.852M shares@ $21.22 avg price
NBIXNeurocrine Biosciences Inc
Recent Activity
Increased 90.54%
2.27%
$151.697M
1.317M shares@ $115.23 avg price
IDYAIdeaya Biosciences Inc
Recent Activity
Increased 23.7%
1.23%
$82.178M
2.594M shares@ $31.68 avg price
BAXBaxter Intl Inc
Recent Activity
Increased 21.9%
1.1%
$73.02M
1.923M shares@ $37.97 avg price
ALNYAlnylam Pharmaceuticals Inc
Recent Activity
Increased 21.04%
0.6%
$39.879M
145,000 shares@ $275.03 avg price
EMBCEmbecta Corp
Recent Activity
Increased 0.16%
0.58%
$38.498M
2.73M shares@ $14.1 avg price
PHVSPharvaris N V
Recent Activity
Increased 45.41%
0.57%
$37.627M
2.032M shares@ $18.52 avg price